Search Results
Year | ID | Type | Category | Title | Authors |
---|
2023 | MOC11 | Poster | Methods of Care |
Safety and Efficacy of Ocrelizumab in a Dialyzed Patient with Chronic Kidney Disease and Multiple Sclerosis. Case Report |
Wolfgang Trillo Álvarez, MD PROF, Gabriel A Calderón Paiva, Med Student, Joshua A Medina Suárez, Med Student, Juan I.S. Valdivia Pino, Med Student, Patrick F Gonzales Romero, Med Student, Luis J Delgado Villanueva, Med Student, Angélica M Flores Quispe, Med Student, Grace N García Huaman, Med Student, Pedro G Chirinos Mamani, Med Student and Zelitt Del Castillo Carrasco, Med Student, Human Medicine, SINAPSIS-UCSM, Arequipa, Peru |
2023 | MOC12 | Poster | Methods of Care |
Educating Social Workers about Multiple Sclerosis: A National Pilot Study |
A. Suzanne Boyd, PhD, MSW, ACSW, FNAP, School of Social Work, University of North Carolina at Charlotte, Charlotte, NC and Research Team |
2023 | MOC13 | Poster | Methods of Care |
Concordance between People with Multiple Sclerosis- and Provider-Reported Disease Course in a Real-World Cohort |
Albert Aboseif, DO1, Moein Amin, MD2, Gabrielle Macaron, MD2 and Daniel Ontaneda, MD PhD2, (1)Department of Neurology, Cleveland Clinic, Cleveland, OH, (2)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH |
2023 | MOC14 | Poster | Methods of Care |
To What Extent Do Studies of Digital Health Technologies for Persons With MS Consider Usability Principles During Development and Evaluation? |
Afolasade Fakolade, PhD, School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, Adam Groh, M.Sc., The Montreal Neurological Institute and Hospital, Montreal, QC, Canada, Colleen Lacey, M.Sc., Psychology, University of Victoria, Victoria, BC, Canada; Institute on Aging and Lifelong Health, Victoria, BC, Canada and Fiona Tea, Ph.D., The Research Centre of the University of Montreal Hospital Centre (CRCHUM), Montreal, QC, Canada |
2023 | MOC16 | Poster | Methods of Care |
A Safety Monitoring Program for Infusion Disease Modifying Therapies for Multiple Sclerosis: Updates on Implementation |
Shuvro Roy, MD, Janel Haughton, RN and Scott D Newsome, DO, MSCS, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | MOC17 | Poster | Methods of Care |
Describing and Evaluating the Clinical Pharmacist’s Role in a Canadian Multiple Sclerosis Clinic |
Gabrielle Busque, BSc, PharmD, ACPR1, Henry Halapy, BScPhm, ACPR, PharmD1, Sharan Lail, BScPhm, ACPR, PharmD1 and Norman Dewhurst, BScPhm, ACPR, PharmD, MHSc2, (1)Pharmacy, Unity Health Toronto, Toronto, ON, Canada, (2)Ambulatory Clinics, Emergency and Medicine Program, Unity Health Toronto, Toronto, ON, Canada |
2023 | MOC18 | Poster | Methods of Care |
Improving Access to High Quality Multiple Sclerosis Specialty Care By Creating a Center for Comprehensive MS Care in North Idaho. |
Katherine Gwin, RN, BSN, MSCS, MSCN, Kaelianne Newbold, RN, BSN, MSCS, MSCN, Autumn Ramsrud, PharmD, CSP, MSCS, Tyler Cress, PharmD, MSCS, Cindy Smith, PharmD, CSP, Angie Critchfield, CPhT and Nina Bozinov, MD, MS, Neurology, Kootenai Clinic, Coeur d’Alene, ID |
2023 | MOC19 | Poster | Methods of Care |
Writing for Wellness: An Innovative Creative Writing Program for People with MS. |
Dotty Holcomb Doherty, N/A1, Nicole Delcourt, RN1, Ann Cabot, DO2 and Brant J. Oliver, PhD, MS, MPH, APRN-BC3, (1)Multiple Sclerosis Specialty Care Program, Concord Hospital, Concord, NH, (2)Multidisciplinary Multiple Sclerosis Clinic at Concord Hospital, Concord, NH, (3)Community of Family and Medicine, Dartmouth Health, Lebanon, NH |
2023 | MOC20 | Poster | Methods of Care |
Can Shared Experiences in Community Change Perspective? |
Emily Blosberg, BS and Andrea Blosberg, BA, MA, Mr Oscar Monkey, Menomonie, WI |
2023 | MOC21 | Poster | Methods of Care |
National MS Society Hispanic/Latinx MS Experience Summit, a Culturally Responsive and Bilingual Virtual Education Program for People Affected By MS |
Eric Garmon, MCHES, MS Navigator Experience, National MS Society, Denver, CO and Aportela, I., Barnola, A., Benson, T., Cohrs, R., Cummings, S., Doherty, E., Fegan, A., Goff, K., Liserio, E., Mastroianni, S., Marshall, J., Saxton, L., Serratoni, M., Stewart, K., Tauchman, J., Wiehardt, G., Wise, J. |
2023 | MOC22 | Poster | Methods of Care |
National MS Society Pathways to Wellness in MS: Nutrition, a Virtual Educational Program for People Affected By MS |
Eric Garmon, MCHES, MS Navigator Experience, National MS Society, Denver, CO and Benson, T., Bostick, M., Goff, K., Henderson, L. Liserio, E., Nearhood, H., Saxton, L., Tauchman, J., Yadav, V., Zackowski, K |
2023 | MOC23 | Poster | Methods of Care |
The National MS Society and the International Pediatric MS Study Group Launch International Pediatric ECHO MS |
Lily Martinez, MPH, The National Multiple Sclerosis Society, Dallas, TX, Thaís Armangué, MD, PhD, Sant Joan de Deu, Barcelona Hospital, Barcelona, Spain, Brenda Banwell, MD, FRCPC, FAAN, The Children’s Hospital of Philadelphia, Philadelphia, PA, Frederik Barkhof, MD, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, Jennifer Graves, MD, PhD, MAS, University of California San Diego, San Diego, CA, Cheryl Hemingway, MBChB, PhD, Great Ormond Street Children’s Hospital, London, United Kingdom, Barbara Kornek, MD, Medical University of Vienna, Vienna, Austria, Hope Nearhood, MPH, The National Multiple Sclerosis Society, Denver, CO, Lekha Pandit, MD, DM, PhD, Nitte University, Karnataka, India and Darren Ball, M.Ed., The National Multiple Sclerosis Society, New York, NY |
2023 | MOC24 | Poster | Methods of Care |
Improving Minority Inclusion in MS Research: Patient Engagement in Survey Development |
Michael V Robers, MD MS1, Vanessa I Martinez, MS1, Hollie Schmidt, MS2, Patricia Teran, MS1, Tiffany Tran, BS1, Huiam Mubarak, MD MS1, Aimee Borazanci, MD1 and Lilyana Amezcua, MD, MS3, (1)Neurology, Barrow Neurological Institute, Phoenix, AZ, (2)Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, (3)Keck School of Medicine, University of Southern California, Los Angeles, CA |
2023 | MOC25 | Poster | Methods of Care |
Neurology Resident Curriculum in Multiple Sclerosis |
Rae Bacharach, DO1, Jikku Zachariah, DO1, Benjamin Bird, MD1 and Elizabeth Sinz, MD2, (1)Neurology, Penn State Milton S. Hershey Medical Center, Hershey, PA, (2)Anesthesiology, Critical Care Medicine, and Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA |
2023 | MOC26 | Poster | Methods of Care |
Dual Diagnosis of MS and Nmosd, Case Series |
Mirla Avila, MD, Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, Martin Sandoval, student, Texas Tech Health science center, Lubbock, TX and Hannah Jackson, student, Texas Tech health science center, Lubbock, TX |
2023 | MOC27 | Poster | Methods of Care |
Assessment of Patient Knowledge in Pregnancy and Multiple Sclerosis |
Kristen Veal, MD1, Elijah Lackey, MD1 and Suma Shah, MD2, (1)MS and Neuroimmunology, Duke University Hospital, Durham, NC, (2)Department of Neurology, Duke University, Durham, NC |
2023 | MOC28 | Poster | Methods of Care |
Feasibility of Obtaining Safety Screening Labs in an Academic Neurology Clinic to Accelerate Time to Anti-CD20 Initiation |
Stephanie Gandelman, MD, Laura Stein, MD, MSEd and Dina Jacobs, MD, Department of Neurology, University of Pennsylvania, Philadelphia, PA |
2023 | NIB01 | Poster | Non-imaging biomarkers |
Preliminary Analyses of a Multiple Sclerosis Cohort Using a Patient Questionnaire for Disability Determination |
Andrew M Tarr, MD1,2, Nadia Azad, BS3, Christina Fournier, MD1,2 and William Tyor, MD1,2, (1)Neurology, Atlanta VA Medical Center, Decatur, GA, (2)Neurology, Emory University, Atlanta, GA, (3)School of Medicine, Emory University, Atlanta, GA |
2023 | NIB02 | Poster | Non-imaging biomarkers |
Eye Movement Biomarkers for Early Detection of Multiple Sclerosis Disease Progression |
Paul S. Giacomini, MD1, Natacha Bastien, Ph.D.2, Patrice Voss, Ph.D.3, Francois Blanchette, Ph.D.2, Francis Arseneau, Ms3, Shamiza Hussein, PMP2, Rosemberg Ramos, Ms3 and Etienne de Villers-Sidani, MD3, (1)Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (2)Medical Affairs, Novartis Pharma Canada, Dorval, QC, Canada, (3)Innodem Neurosciences, Montreal, QC, Canada |
2023 | NIB03 | Poster | Non-imaging biomarkers |
Biomarkers in Multiple Sclerosis Progression; Promises and Challenges |
Sara Esmaeili, Research Fellow, Neurology, University of Cincinnati, Cincinnati, OH and Aram Zabeti, MD, Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH |
2023 | NIB04 | Poster | Non-imaging biomarkers |
Bile Acid and Fatty Acid Metabolisms Are Associated with Multiple Sclerosis Severity. |
Elina Misicka, Ph.D, Case Western Reserve University, Cleveland, OH and Farren B.S. Briggs, PhD, ScM, Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH |
2023 | NID01 | Poster | Neuroimmunology and disease models |
Mortality Estimates in Patients with Anti-Aquaporin-4 Autoantibody Positive Neuromyelitis Optica Spectrum Disorder |
Adrian Kielhorn, BA1, Jacqueline Palace, DM2, Nina Eagle, MS2, M Isabel Leite, MS2, Lauren Powell, BSc, MSc, PhD3 and Karissa Johnston, BSc, MSc, PhD3, (1)Alexion, AstraZeneca Rare Disease, Boston, MA, (2)Oxford University Hospital, Oxford, United Kingdom, (3)BroadStreet Health Economics & Outcomes Research, Vancouver, BC, Canada |
2023 | NID02 | Poster | Neuroimmunology and disease models |
The Innate Immune Regulator NLRX1 Limits Visual Pathway Neurodegeneration in Spontaneous Experimental Autoimmune Encephalomyelitis |
Alexander J Gill, MD, PhD, Marjan Gharagozloo, PhD, Thomas Garton, B.S., Matt Smith, M.S. and Peter A Calabresi, MD, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | NID03 | Poster | Neuroimmunology and disease models |
COVID-19 Hospitalization in Fully Vaccinated Patients with MS and Related Disorders Treated with Anti-CD20 Therapies (aCD20) |
Austin Chen, MD1, Francesca Chinea, BA2, Gary Cutter, PhD3, Lauren Krupp, MD1, Ilya Kister, MD1, Lana Zhovtis Ryerson, M.D.1 and Tyler E Smith, M.D.1, (1)Neurology, NYU Langone Health, New York, NY, (2)NYU, New York, NY, (3)University of Alabama School of Public Health, Birmingham, AL |
2023 | NID04 | Poster | Neuroimmunology and disease models |
Characterizing the Impact of Nmosd on Mobility, Daily Activities, and Social Activities through Patient Interviews |
Evanthia Bernitsas, MD1, Benjamin Osborne, MD2, Natalie Taylor, MPH3, Fanyang Zeng, MPH3, Milena Anatchkova, PhD3 and Adrian Kielhorn, BA4, (1)Wayne State University School of Medicine, Detroit, MI, (2)Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, (3)Evidera, Bethesda, MD, (4)Alexion, AstraZeneca Rare Disease, Boston, MA |
2023 | NID05 | Poster | Neuroimmunology and disease models |
Transcriptomic Analysis Reveals That RGC-32 Regulates the Expression of Axonal Guidance Molecules in Reactive Astrocytes |
Jacob A Cuevas, B.S.1, Alexandru Tatomir, MD1, Vinh Nguyen, DMD2, Tudor Badea, MD/PhD3, Violeta Rus, MD/PhD2 and Horea Rus, MD, PhD4, (1)Neurology, University of Maryland, Baltimore, MD, (2)Medicine, University of Maryland, Baltimore, MD, (3)Research and Development Institute, Transylvania University of Brasov, Brasov, Romania, (4)Veterans Administration Multiple Sclerosis Center of Excellence, Baltimore, MD |
2023 | NID06 | Poster | Neuroimmunology and disease models |
Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder: 3 Years of Data from a Japanese Post-Marketing Surveillance Study |
Jin Nakahara, MD, PhD1, Ichiro Nakashima, MD, PhD2, Hiroaki Yokote, MD3, Yasuhiro Manabe, MD4, Kazumi Okamura, MD5, Kou Hasegawa, PhD5 and Kazuo Fujihara, MD6,7, (1)Department of Neurology, Keio University School of Medicine, Tokyo, Japan, (2)Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, (3)Department of Neurology, Nitobe Memorial Nakano General Hospital, Tokyo, Japan, (4)Department of Neurology, National Hospital Organization Okayama Medical Center, Okayama, Japan, (5)Alexion Pharma GK, Tokyo, Japan, (6)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (7)Fukushima Medical University School of Medicine, Fukushima, Japan |
2023 | NID07 | Poster | Neuroimmunology and disease models |
Sensitivity Analysis Using Propensity Score Methods for Primary Efficacy Outcome in the Champion-Nmosd Trial |
Kerstin Allen, MA1, Sean J Pittock, MD2, Michael Levy, MD, PhD3, Jacqueline Palace, DM4, Celia Oreja-Guevara, MD5,6, Ichiro Nakashima, MD, PhD7,8, Achim Berthele, MD9, Jeffrey L Bennett, MD, PhD10, Jerome de Seze, MD, PhD11, Michael Barnett, PhD, MD12,13, Friedemann Paul, MD14, Carlo Pozzilli, MD, PhD15, Yasmin Mashhoon, PhD1, Marcus Yountz, MD1 and Ho Jin Kim, MD16, (1)Alexion, AstraZeneca Rare Disease, Boston, MA, (2)Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, (3)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (4)Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom, (5)Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain, (6)Hospital Clinico San Carlos, Madrid, Spain, (7)Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan, (8)Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, (9)Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, (10)University of Colorado School of Medicine, Aurora, CO, (11)Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France, (12)Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia, (13)Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, (14)Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, (15)NCL Institute of Neurological Science, Rome, Italy, (16)Department of Neurology, National Cancer Center, Goyang, Korea, Republic of (South) |
2023 | NID08 | Poster | Neuroimmunology and disease models |
Clinical Outcomes of COVID-19 Infection Among Patients with Neuromyelitis Optica Spectrum Disorder Receiving Inebilizumab Treatment in the N-Momentum Trial and Safety Database in the United States |
Bruce A.C. Cree, MD1, Mary Rensel, MD2, Sean J Pittock, MD3, Aram Zabeti, MD4, Ho-Jin Kim, MD5, Friedemann Paul, MD6, Derrick S Robertson, MD7, Kristina R Patterson, MD, PhD8, Qing Li, MD, PhD9, Quinn Dinh, MD9 and Michael Levy, MD, PhD10, (1)Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)Neurology, Cleveland Clinic, Cleveland, OH, (3)Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, (4)Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, (5)Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (6)Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, (7)Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, (8)Horizon Therapeutics, Deerfield, IL, (9)Horizon Therapeutics plc, Deerfield, IL, (10)Massachusetts General Hospital and Harvard Medical School, Boston, MA |
2023 | NID09 | Poster | Neuroimmunology and disease models |
Effect of Inebilizumab on Vaccine-Generated Antibody Titers in Neuromyelitis Optica Spectrum Disorder Participants: Results from N-Momentum Study |
Hans-Peter Hartung, MD, FRCP, FEAN, FAAN, FANA1,2,3,4, Brian G Weinshenker, MD5, Sean J Pittock, MD6, Jeffrey L Bennett, MD, PhD7, Michael A Smith, PhD8, Nanette Mittereder, MS8, William A Rees, PhD8, Daniel Cimbora, PhD8, Kristina R Patterson, MD, PhD8, Friedemann Paul, MD9, Romain Marignier, MD10, Dean M Wingerchuk, MD11, Gary Cutter, MS, PhD12, Ari Green, MD13, Ho-Jin Kim, MD14, Kazuo Fujihara, MD15,16, Michael Levy, MD, PhD17, Orhan Aktas, MD18 and Bruce A.C. Cree, MD19, (1)Department of Neurology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, (2)Brain and Mind Centre, University of Sydney, Sydney, Australia, (3)Department of Neurology, Medical University Vienna, Vienna, Austria, (4)Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic, (5)Department of Neurology, University of Virginia, Charlottesville, VA, (6)Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, (7)University of Colorado School of Medicine, Aurora, CO, (8)Horizon Therapeutics, Deerfield, IL, (9)Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, (10)Department of Neurology, MS, Myelin Pathologies, and Neuroinflammation, Lyon University Hospital, Lyon, France, (11)Department of Neurology, Mayo Clinic, Scottsdale, AZ, (12)Department of Biostatistics, UAB School of Public Health, Birmingham, AL, (13)Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, San Francisco, CA, (14)Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (15)Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (16)Fukushima Medical University School of Medicine, Fukushima, Japan, (17)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (18)Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany, (19)Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA |
2023 | NID10 | Poster | Neuroimmunology and disease models |
Maximal Cellular Immune Response to Sars-Cov-2 mRNA Vaccines Is Attained after Second but Not Third Vaccine, and Is Only Modestly Affected By Treatment with Natalizumab, Ocrelizumab or Fumarates |
Pavle Repovic, MD, PhD1, Jongchan Choi, PhD2, Sunga Hong, PhD2, Lik W Lee, PhD3, Darcy B. Gill, PhD3, James D. Bowen, MD1, Peiqing Qian, MD1, Simon Evans, PhD2, Rick Edmark, PhD2, Jason P. Mendoza, PhD4, Robin L. Avila, PhD4, Jim Heath, PhD2 and Jason Goldman, MD, MPH5, (1)Swedish Neuroscience Institute, Seattle, WA, (2)Institute for Systems Biology, Seattle, WA, (3)Adaptive Biotechnologies, Seattle, WA, (4)Biogen, Cambridge, MA, (5)Swedish Medical Center, Seattle, WA |
2023 | NID11 | Poster | Neuroimmunology and disease models |
Efficacy and Safety of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Outcomes from the Phase 3 Champion-Nmosd Trial |
Sean J Pittock, MD1, Michael Barnett, PhD, MD2,3, Jeffrey L Bennett, MD, PhD4, Achim Berthele, MD5, Jerome de Seze, MD, PhD6, Michael Levy, MD, PhD7, Ichiro Nakashima, MD, PhD8,9, Celia Oreja-Guevara, MD10,11, Jacqueline Palace, DM12, Friedemann Paul, MD13, Carlo Pozzilli, MD, PhD14, Kerstin Allen, MA15, Yasmin Mashhoon, PhD15, Marcus Yountz, MD15 and Ho Jin Kim, MD16, (1)Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, (2)Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia, (3)Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, (4)University of Colorado School of Medicine, Aurora, CO, (5)Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, (6)Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France, (7)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (8)Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan, (9)Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, (10)Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain, (11)Hospital Clinico San Carlos, Madrid, Spain, (12)Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom, (13)Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, (14)Department of Human Neuroscience, La Sapienza University, Rome, Italy, (15)Alexion, AstraZeneca Rare Disease, Boston, MA, (16)Department of Neurology, National Cancer Center, Goyang, Korea, Republic of (South) |
2023 | NID12 | Poster | Neuroimmunology and disease models |
Efficacy Subgroup Analyses from the Phase 3 Champion-Nmosd Trial in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder |
Sean J Pittock, MD1, Michael Barnett, PhD, MD2,3, Jeffrey L Bennett, MD, PhD4, Achim Berthele, MD5, Jerome de Seze, MD, PhD6, Michael Levy, MD, PhD7, Ichiro Nakashima, MD, PhD8,9, Celia Oreja-Guevara, MD10,11, Jacqueline Palace, DM12, Friedemann Paul, MD13, Carlo Pozzilli, MD, PhD14, Kerstin Allen, MA15, Yasmin Mashhoon, PhD15, Marcus Yountz, MD15 and Ho Jin Kim, MD16, (1)Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, (2)Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia, (3)Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, (4)University of Colorado School of Medicine, Aurora, CO, (5)Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, (6)Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France, (7)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (8)Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan, (9)Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, (10)Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain, (11)Hospital Clinico San Carlos, Madrid, Spain, (12)Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom, (13)Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, (14)NCL Institute of Neurological Science, Rome, Italy, (15)Alexion, AstraZeneca Rare Disease, Boston, MA, (16)Department of Neurology, National Cancer Center, Goyang, Korea, Republic of (South) |
2023 | NID13 | Poster | Neuroimmunology and disease models |
Predicting the Final Clinical Phenotype after the First Attack of Optic Neuritis |
Shlok Sarin, BS1, Nikhil Modak, MD2, Rongyi Sun, BS3, Omar Subei, MD4, Alessandro Serra, MD, PhD5, Michael Morgan, MD, PhD6 and Hesham Abboud, MD, PhD3, (1)Case Western Reserve School of Medicine – – Cleveland Heights, OH, Cleveland, OH, (2)University Hospitals of Cleveland, Cleveland, OH, (3)Case Western Reserve University School of Medicine, Cleveland, OH, (4)Duke University Medical Center, Durham, NC, (5)Multiple Sclerosis and Neuroimmunology program, University Hospitals Cleveland Medical Center, Cleveland, OH, (6)University Hospitals Cleveland Medical Center, Cleveland, OH |
2023 | NID14 | Poster | Neuroimmunology and disease models |
Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder during the Phase 3 Champion-Nmosd Trial |
Sean J Pittock, MD, Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, Achim Berthele, MD, Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, Ichiro Nakashima, MD, PhD, Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan; Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Celia Oreja-Guevara, MD, Department of Neurology, Hospital Clínico Universitario San Carlos, IdISSC, Madrid, Spain; Hospital Clinico San Carlos, Madrid, Spain, Stephan Ortiz, Ph.D., Alexion, AstraZeneca Rare Disease, Boston, MA and Ho Jin Kim, MD, Department of Neurology, National Cancer Center, Goyang, Korea, Republic of (South) |
2023 | NID15 | Poster | Neuroimmunology and disease models |
Patterns and Predictors of Multiple Sclerosis Phenotype Transitions Based on a Longitudinal Analysis Using the CLIMB Study |
Gauruv Bose, MD1,2, Nupur Greene, PhD, MPH, BPharm3, Brian C. Healy, PhD1, Howard L. Weiner, MD4,5, Lisa Farnett, PharmD3, Keiko Higuchi, MPH3 and Tanuja Chitnis, MD5,6, (1)Brigham and Women’s Hospital, Boston, MA, (2)Department of Medicine (Neurology), University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada, (3)Sanofi, Cambridge, MA, (4)Brigham and Women’s Hospital, Boston, MA, (5)Harvard Medical School, Boston, MA, (6)Brigham and Women’s Hospital, Harvard Medical School, Boston, MA |
2023 | NNN01 | Poster | Neurophysiology; Neuropsychology and neuropsychiatry |
Understanding Prospective Memory in Multiple Sclerosis: How Are Objective and Subjective Measures Related and Who Experiences Problems |
Elizabeth S Gromisch, PhD, MSCS1,2,3, Aaron P Turner, Ph.D. ABPP (RP)4,5,6, Lindsay O Neto, MPH1,7 and Sarah A Raskin, PhD8,9, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (5)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (6)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (7)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (8)Neuroscience Program, Trinity College, Hartford, CT, (9)Department of Psychology, Trinity College, Hartford, CT |
2023 | NNN02 | Poster | Neurophysiology; Neuropsychology and neuropsychiatry |
Using Visual Imagery and Implementation Intentions to Improve Prospective Memory in Multiple Sclerosis: Preliminary Results from a Telehealth Feasibility Trial |
Elizabeth S Gromisch, PhD, MSCS1,2,3, Aaron P Turner, Ph.D. ABPP (RP)4,5,6, Lindsay O Neto, MPH1,7, Jodie Haselkorn, MD, MPH4,5,6,8 and Sarah A Raskin, PhD9,10, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (5)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (6)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (7)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (8)Department of Epidemiology, University of Washington, Seattle, WA, (9)Neuroscience Program, Trinity College, Hartford, CT, (10)Department of Psychology, Trinity College, Hartford, CT |
2023 | NNN03 | Poster | Neurophysiology; Neuropsychology and neuropsychiatry |
Do Depression and Anxiety Symptoms Influence the Construct Validity of Multiple Sclerosis Walking Scale-12 Scores? |
Petra Šili?, BS1, Danielle C Jones, MPH2, Brenda Jeng, Ph.D1 and Robert W. Motl, PhD1, (1)Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL, (2)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL |
2023 | NNN04 | Poster | Neurophysiology; Neuropsychology and neuropsychiatry |
Information Processing Speed and Social Cognition in Individuals with Multiple Sclerosis and Co-Morbid Diabetes: A Preliminary Analysis |
Sanghamithra Ramani, BSc1,2, Jordan D. Pumphrey, BSc2,3, Jason A. Berard, PhD4, Matthew Seegobin, MSc.2, Jing Wang, PhD2,4, Jennifer M Lymer, PhD, MD5 and Lisa A.S. Walker, PhD, C. Psych1,2,3,4, (1)Psychology, Carleton University, Ottawa, ON, Canada, (2)Ottawa Hospital Research Institute, Ottawa, ON, Canada, (3)Psychology, University of Ottawa, Ottawa, ON, Canada, (4)University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada, (5)University of Ottawa, Ottawa, ON, Canada |